Business Context and Reporting Period
Sight Sciences, Inc. (SGHT) filed a Form 8-K on August 27, 2025, announcing a targeted restructuring plan to reduce operating expenses and align its structure for long-term profitable growth. The company aims to maintain its path to breakeven without requiring additional equity capital.
Key Financial Metrics and Restructuring Costs
- Restructuring Charge: Expected cash charge of $2.7 million to $3.0 million in Q3 2025, primarily for severance and benefits.
- Stock-Based Compensation: Expected non-cash reduction of $0.6 million to $1.0 million in Q3 2025.
- Annualized Savings: Workforce reductions are estimated to yield approximately $11.9 million in annualized savings.
- Headcount Reduction: Reduction of 43 employees, representing approximately 20% of the global workforce.
Material Changes and Operational Adjustments
The company is implementing a plan to reduce headcount by 20%, with 45% of impacted employees in general and administrative functions. The remaining reductions are split between R&D/clinical and sales functions. Operational changes include delaying certain R&D spend, reducing SG&A costs (marketing, travel, admin), and not backfilling open positions. Additionally, the company is creating segment-specific leadership for Surgical Glaucoma and Dry Eye business units.
Matthew Link is stepping down as Chief Commercial Officer effective August 31, 2025. His severance package, including one year of base salary, COBRA benefits, and accelerated vesting of 61,675 RSUs, is included in the estimated restructuring costs.
Guidance, Outlook, and Management Commentary
- 2025 Revenue Guidance: Reaffirmed at $72.0 million to $76.0 million.
- Q3 2025 Surgical Glaucoma Revenue: Expected to be down by mid-single digits compared to the prior year period.
- 2025 Adjusted Operating Expenses: Updated guidance to $95 million to $99 million, down from the previous $101 million to $105 million.
- Non-GAAP Reporting: The company plans to present non-GAAP financial measures for Q3 and full-year 2025 excluding non-core operating costs related to the restructuring.
Investor Verification Checklist
- Verify the final cash restructuring charge amount in the Q3 2025 earnings release against the $2.7M-$3.0M estimate.
- Confirm the actual headcount reduction and the specific distribution across business units.
- Monitor the execution of the UK operational changes, which are subject to local notice and consultancy requirements.
- Track the Q3 2025 surgical glaucoma revenue performance to confirm the mid-single digit decline.
- Review the upcoming Q3 2025 financial statements for the presentation of non-GAAP measures excluding restructuring costs.